CardioRenal Systems

CardioRenal Systems is a Massachusetts-based medical device company developing innovative technologies for the prevention and treatment of AKI in general hospitalized patients, including those undergoing cardiac surgery, interventional cardiology, and ICU care. Results from the KIDNEY study (a randomized controlled clinical trial involving 220 patients) showed that RenalGuard Therapy® reduced AKI by 52% compared to standard care.